Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

Caitlin E. Cox

October 25, 2023

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

Presentation TCT 2016

TCT 74: A Serial Three-Year and Nine-Year Optical Coherence Tomography Assessment of Vascular Healing Response to Sirolimus and Paclitaxel-Eluting Stents

Presenter: Hector M. Garcia-Garcia, Ik-Kyung Jang, Mariusz Tomaniak

October 31, 2016

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

Presentation TCT 2014

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Presenter: Georgios Vlachojannis

September 16, 2014

News Conference News TCT 2014

Keynote Address Focuses on Newer DES, Problematic Subgroups

September 15, 2014

Presentation TCT 2014

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Presenter: Gregg W. Stone, Pieter C. Smits, Fernando Alfonso

September 14, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

News Conference News TCT 2013

PCI vs. CABG a Close Call in Some Complex Patients

October 30, 2013

Presentation TCT 2013

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

Presenter: Peter Smits

October 29, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Presenter: Piotr Buszman

October 28, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

What’s Going to Be Hot at TCT 2025

Comparing DCBs in De Novo CAD: Drugs, Design Matter

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

TCT 74: A Serial Three-Year and Nine-Year Optical Coherence Tomography Assessment of Vascular Healing Response to Sirolimus and Paclitaxel-Eluting Stents

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Second-Generation DES, DCB Both Strategies for Treating In-Stent Restenosis

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing primary percutaneous coronary intervention: 5 year follow-up from the COMPARE I___

Keynote Address Focuses on Newer DES, Problematic Subgroups

RIBS IV: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

PCI vs. CABG a Close Call in Some Complex Patients

TCT-13. Final Five Year Results From The All-comer COMPARE Trial: A Prospective, Randomized Trial of Everolimus-Eluting vs. Paclitaxel-Eluting Stents

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Cre8, BioFreedom Polymer-Free DES Show Promise

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content